472 related articles for article (PubMed ID: 23889535)
1. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567.
Bhattacharya A; Wang Q; Ao H; Shoblock JR; Lord B; Aluisio L; Fraser I; Nepomuceno D; Neff RA; Welty N; Lovenberg TW; Bonaventure P; Wickenden AD; Letavic MA
Br J Pharmacol; 2013 Oct; 170(3):624-40. PubMed ID: 23889535
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432.
Lord B; Aluisio L; Shoblock JR; Neff RA; Varlinskaya EI; Ceusters M; Lovenberg TW; Carruthers N; Bonaventure P; Letavic MA; Deak T; Drinkenburg W; Bhattacharya A
J Pharmacol Exp Ther; 2014 Dec; 351(3):628-41. PubMed ID: 25271258
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia.
Bhattacharya A; Lord B; Grigoleit JS; He Y; Fraser I; Campbell SN; Taylor N; Aluisio L; O'Connor JC; Papp M; Chrovian C; Carruthers N; Lovenberg TW; Letavic MA
Neuropsychopharmacology; 2018 Dec; 43(13):2586-2596. PubMed ID: 30026598
[TBL] [Abstract][Full Text] [Related]
4. A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334.
Lord B; Ameriks MK; Wang Q; Fourgeaud L; Vliegen M; Verluyten W; Haspeslagh P; Carruthers NI; Lovenberg TW; Bonaventure P; Letavic MA; Bhattacharya A
Eur J Pharmacol; 2015 Oct; 765():551-9. PubMed ID: 26386289
[TBL] [Abstract][Full Text] [Related]
5. Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy.
Jimenez-Pacheco A; Diaz-Hernandez M; Arribas-Blázquez M; Sanz-Rodriguez A; Olivos-Oré LA; Artalejo AR; Alves M; Letavic M; Miras-Portugal MT; Conroy RM; Delanty N; Farrell MA; O'Brien DF; Bhattacharya A; Engel T; Henshall DC
J Neurosci; 2016 Jun; 36(22):5920-32. PubMed ID: 27251615
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139.
Hopper AT; Juhl M; Hornberg J; Badolo L; Kilburn JP; Thougaard A; Smagin G; Song D; Calice L; Menon V; Dale E; Zhang H; Cajina M; Nattini ME; Gandhi A; Grenon M; Jones K; Khayrullina T; Chandrasena G; Thomsen C; Zorn SH; Brodbeck R; Poda SB; Staal R; Möller T
J Med Chem; 2021 Apr; 64(8):4891-4902. PubMed ID: 33822617
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of
Kolb HC; Barret O; Bhattacharya A; Chen G; Constantinescu C; Huang C; Letavic M; Tamagnan G; Xia CA; Zhang W; Szardenings AK
J Nucl Med; 2019 Aug; 60(8):1154-1159. PubMed ID: 30733317
[TBL] [Abstract][Full Text] [Related]
8. Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat.
Able SL; Fish RL; Bye H; Booth L; Logan YR; Nathaniel C; Hayter P; Katugampola SD
Br J Pharmacol; 2011 Jan; 162(2):405-14. PubMed ID: 20840537
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
[TBL] [Abstract][Full Text] [Related]
10. Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1
Ruiz-Ruiz C; García-Magro N; Negredo P; Avendaño C; Bhattacharya A; Ceusters M; García AG
Dis Model Mech; 2020 Oct; 13(10):. PubMed ID: 33174532
[TBL] [Abstract][Full Text] [Related]
11. [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.
Donnelly-Roberts DL; Namovic MT; Surber B; Vaidyanathan SX; Perez-Medrano A; Wang Y; Carroll WA; Jarvis MF
Neuropharmacology; 2009 Jan; 56(1):223-9. PubMed ID: 18602931
[TBL] [Abstract][Full Text] [Related]
12. The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1
Ly D; Dongol A; Cuthbertson P; Guy TV; Geraghty NJ; Sophocleous RA; Sin L; Turner BJ; Watson D; Yerbury JJ; Sluyter R
Purinergic Signal; 2020 Mar; 16(1):109-122. PubMed ID: 32170537
[TBL] [Abstract][Full Text] [Related]
13. The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice.
Honore P; Donnelly-Roberts D; Namovic M; Zhong C; Wade C; Chandran P; Zhu C; Carroll W; Perez-Medrano A; Iwakura Y; Jarvis MF
Behav Brain Res; 2009 Dec; 204(1):77-81. PubMed ID: 19464323
[TBL] [Abstract][Full Text] [Related]
14. Translational Model-Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ-54175446, a P2X7 Receptor Antagonist.
Xu Y; Miao X; Ravenstijn P; Hijzen A; Schmidt ME; Nandy P; Zhou H
Clin Transl Sci; 2020 Mar; 13(2):309-317. PubMed ID: 31642608
[TBL] [Abstract][Full Text] [Related]
15. P2X
Yin J; Wang Y; Hu H; Li X; Xue M; Cheng W; Wang Y; Li X; Yang N; Shi Y; Yan S
J Cell Mol Med; 2017 Nov; 21(11):2695-2710. PubMed ID: 28470940
[TBL] [Abstract][Full Text] [Related]
16. P2X7 Purinergic Receptor Is Involved in the Pathophysiology of Mania: a Preclinical Study.
Gubert C; Andrejew R; Leite CE; Moritz CEJ; Scholl J; Figueiro F; Kapczinski F; da Silva Magalhães PV; Battastini AMO
Mol Neurobiol; 2020 Mar; 57(3):1347-1360. PubMed ID: 31729632
[TBL] [Abstract][Full Text] [Related]
17. P2X7 receptor-mediated release of microglial prostanoids and miRNAs correlates with reversal of neuropathic hypersensitivity in rats.
Staal R; Khayrullina T; Christensen R; Hestehave S; Zhou H; Cajina M; Nattini ME; Gandhi A; Fallon SM; Schmidt M; Zorn SH; Brodbeck RM; Chandrasena G; Segerdahl M; Breysse N; Hopper AT; Möller T; Munro G
Eur J Pain; 2022 Jul; 26(6):1304-1321. PubMed ID: 35388574
[TBL] [Abstract][Full Text] [Related]
18. P2X7-related modulation of pathological nociception in rats.
McGaraughty S; Chu KL; Namovic MT; Donnelly-Roberts DL; Harris RR; Zhang XF; Shieh CC; Wismer CT; Zhu CZ; Gauvin DM; Fabiyi AC; Honore P; Gregg RJ; Kort ME; Nelson DW; Carroll WA; Marsh K; Faltynek CR; Jarvis MF
Neuroscience; 2007 Jun; 146(4):1817-28. PubMed ID: 17478048
[TBL] [Abstract][Full Text] [Related]
19. Paroxetine suppresses recombinant human P2X7 responses.
Dao-Ung P; Skarratt KK; Fuller SJ; Stokes L
Purinergic Signal; 2015 Dec; 11(4):481-90. PubMed ID: 26341077
[TBL] [Abstract][Full Text] [Related]
20. Substituted 5,6-(Dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 Antagonists.
Ziff J; Rudolph DA; Stenne B; Koudriakova T; Lord B; Bonaventure P; Lovenberg TW; Carruthers NI; Bhattacharya A; Letavic MA; Shireman BT
ACS Chem Neurosci; 2016 Apr; 7(4):498-504. PubMed ID: 26754558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
